SPIROMICS

Subpopulations and Intermediate Outcome Measures in COPD Study
Subpopulations and intermediate outcome measures in COPD study (SPIROMICS) supports the prospective collection and analysis of phenotypic, biomarker, genetic, genomic, and clinical data from subjects with COPD for the purpose of identifying subpopulations and intermediate outcome measures. It is funded by the National Heart, Lung, and Blood Institute and is coordinated by the University of North Carolina at Chapel Hill.

SPIROMICS research participants are enrolled, phenotyped, and followed at twelve SPIROMICS Clinical Centers (in Winston-Salem, NC; Ann Arbor, MI; San Francisco, CA; Los Angeles, CA; New York City, NY; Denver, CO; Iowa City, IA; Chicago, IL; Philadelphia, PA; Baltimore, MD; Birmingham, AL; and Salt Lake City, UT). Molecular fingerprinting and extensive subject phenotyping are performed to identify disease subpopulations and to identify and validate surrogate markers of disease severity which will be useful as intermediate outcome measures for future clinical trials. Secondary aims are to clarify the natural history of COPD, to develop bioinformatic resources that will enable the utilization and sharing of data in studies of COPD and related diseases, and to create a collection of clinical, biomarker, radiographic, and genetic data that can be used by external investigators for other studies of COPD.

Molecular fingerprinting and extensive subject phenotyping are being performed to identify disease subpopulations and to identify and validate surrogate markers of disease severity which will be useful as intermediate outcome measures for future clinical trials. Secondary aims are to clarify the natural history of COPD, to develop bioinformatic resources that will enable the utilization and sharing of data in studies of COPD and related diseases, and to create a collection of clinical, biomarker, radiographic, and genetic data that can be used by external investigators for other studies of COPD. The Coordinating Center PI is David Couper, Ph.D.
Website: SPIROMICS
Clinical Centers: 12
Participants: 3,200
Beginning:
Ending:
Funding: NHLBI and COPD Foundation
Study Design:
Observational study